481 related articles for article (PubMed ID: 37582478)
41. Viral load decrease in SARS-CoV-2 BA.1 and BA.2 Omicron sublineages infection after treatment with monoclonal antibodies and direct antiviral agents.
Mazzotta V; Cozzi Lepri A; Colavita F; Rosati S; Lalle E; Cimaglia C; Paulicelli J; Mastrorosa I; Vita S; Fabeni L; Vergori A; Maffongelli G; Carletti F; Lanini S; Caraffa E; Milozzi E; Libertone R; Piselli P; Girardi E; Garbuglia A; Vaia F; Maggi F; Nicastri E; Antinori A;
J Med Virol; 2023 Jan; 95(1):e28186. PubMed ID: 36184918
[TBL] [Abstract][Full Text] [Related]
42. Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study.
Gentile I; Scotto R; Schiano Moriello N; Pinchera B; Villari R; Trucillo E; Ametrano L; Fusco L; Castaldo G; Buonomo AR; Federico Ii Covid Team
Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298596
[TBL] [Abstract][Full Text] [Related]
43. Impact of the Use of Oral Antiviral Agents on the Risk of Hospitalization in Community Coronavirus Disease 2019 Patients (COVID-19).
Yip TC; Lui GC; Lai MS; Wong VW; Tse YK; Ma BH; Hui E; Leung MKW; Chan HL; Hui DS; Wong GL
Clin Infect Dis; 2023 Feb; 76(3):e26-e33. PubMed ID: 36031408
[TBL] [Abstract][Full Text] [Related]
44. "Saving lives with nirmatrelvir/ritonavir one transplant patient at a time".
Belden KA; Yeager S; Schulte J; Cantarin MPM; Moss S; Royer T; Coppock D
Transpl Infect Dis; 2023 Apr; 25(2):e14037. PubMed ID: 36847419
[TBL] [Abstract][Full Text] [Related]
45. Efficacy and Safety of Nirmatrelvir/Ritonavir, Molnupiravir, and Remdesivir in a Real-World Cohort of Outpatients with COVID-19 at High Risk of Progression: The PISA Outpatient Clinic Experience.
Tiseo G; Barbieri C; Galfo V; Occhineri S; Matucci T; Almerigogna F; Kalo J; Sponga P; Cesaretti M; Marchetti G; Forniti A; Caroselli C; Ferranti S; Pogliaghi M; Polidori M; Fabiani S; Verdenelli S; Tagliaferri E; Riccardi N; Suardi LR; Carmignani C; Batini S; Puccetti L; Iapoce R; Menichetti F; Falcone M
Infect Dis Ther; 2023 Jan; 12(1):257-271. PubMed ID: 36441485
[TBL] [Abstract][Full Text] [Related]
46. Combination regimen of nirmatrelvir/ritonavir and molnupiravir for the treatment of persistent SARS-CoV-2 infection: A case report and a scoping review of the literature.
Marangoni D; Antonello RM; Coppi M; Palazzo M; Nassi L; Streva N; Povolo L; Malentacchi F; Zammarchi L; Rossolini GM; Vannucchi AM; Bartoloni A; Spinicci M
Int J Infect Dis; 2023 Aug; 133():53-56. PubMed ID: 37150351
[TBL] [Abstract][Full Text] [Related]
47. Association of Molnupiravir and Nirmatrelvir-Ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19.
Wai AK; Chan CY; Cheung AW; Wang K; Chan SC; Lee TT; Luk LY; Yip ET; Ho JW; Tsui OW; Cheung KW; Lee S; Tong CK; Yamamoto T; Rainer TH; Wong EL
Lancet Reg Health West Pac; 2023 Jan; 30():100602. PubMed ID: 36212676
[TBL] [Abstract][Full Text] [Related]
48. Comparative effectiveness of nirmatrelvir/ritonavir versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised high-risk patients during Omicron waves: observational cohort study using the OpenSAFELY platform.
Zheng B; Tazare J; Nab L; Green AC; Curtis HJ; Mahalingasivam V; Herrett EL; Costello RE; Eggo RM; Speed V; Bacon SC; Bates C; Parry J; Cockburn J; Hester F; Harper S; Schaffer AL; Hulme WJ; Mehrkar A; Evans SJ; MacKenna B; Goldacre B; Douglas IJ; Tomlinson LA;
Lancet Reg Health Eur; 2023 Nov; 34():100741. PubMed ID: 37927438
[TBL] [Abstract][Full Text] [Related]
49. Oral anti-viral therapy for early COVID-19 infection in patients with haematological malignancies: A multicentre prospective cohort.
Minoia C; Diella L; Perrone T; Loseto G; Pelligrino C; Attolico I; Pasciolla C; Totaro V; De Candia MS; Spada V; Clemente F; Camporeale M; Di Gennaro F; Guarini A; Musto P; Saracino A; Bavaro DF
Br J Haematol; 2023 Sep; 202(5):928-936. PubMed ID: 37259629
[TBL] [Abstract][Full Text] [Related]
50. Outcome of early treatment of SARS-CoV-2 infection in patients with haematological disorders.
Mikulska M; Testi D; Russo C; Balletto E; Sepulcri C; Bussini L; Dentone C; Magne F; Policarpo S; Campoli C; Miselli F; Cilli A; Ghiggi C; Aquino S; Di Grazia C; Giannella M; Giacobbe DR; Vena A; Raiola AM; Bonifazi F; Zinzani P; Cavo M; Lemoli R; Angelucci E; Viale P; Bassetti M; Bartoletti M
Br J Haematol; 2023 May; 201(4):628-639. PubMed ID: 36806152
[TBL] [Abstract][Full Text] [Related]
51. Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a Real-World Setting: A Nationwide Study from England and Italy.
Ciccimarra F; Luxi N; Bellitto C; L' Abbate L; De Nardo P; Savoldi A; Yeomans A; Molokhia M; Tacconelli E; Trifirò G
BioDrugs; 2023 Sep; 37(5):675-684. PubMed ID: 37148526
[TBL] [Abstract][Full Text] [Related]
52. First-generation oral antivirals against SARS-CoV-2.
Sendi P; Razonable RR; Nelson SB; Soriano A; Gandhi RT
Clin Microbiol Infect; 2022 Sep; 28(9):1230-1235. PubMed ID: 35545195
[TBL] [Abstract][Full Text] [Related]
53. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
[TBL] [Abstract][Full Text] [Related]
54. Antiviral drug treatment for nonsevere COVID-19: a systematic review and network meta-analysis.
Pitre T; Van Alstine R; Chick G; Leung G; Mikhail D; Cusano E; Khalid F; Zeraatkar D
CMAJ; 2022 Jul; 194(28):E969-E980. PubMed ID: 35878897
[TBL] [Abstract][Full Text] [Related]
55. The Antiviral Effect of Nirmatrelvir/Ritonavir during COVID-19 Pandemic Real-World Data.
Petrakis V; Rafailidis P; Trypsianis G; Papazoglou D; Panagopoulos P
Viruses; 2023 Apr; 15(4):. PubMed ID: 37112956
[TBL] [Abstract][Full Text] [Related]
56. Nirmatrelvir/ritonavir treatment in SARS-CoV-2 positive kidney transplant recipients - a case series with four patients.
Schneider J; Wobser R; Kühn W; Wagner D; Tanriver Y; Walz G
BMC Nephrol; 2023 Apr; 24(1):99. PubMed ID: 37061677
[TBL] [Abstract][Full Text] [Related]
57. Effect of pre-hospitalization use of oral antiviral agents on reducing critical illness and mortality for patients with COVID-19 pneumonia.
Yii YC; Shih HM; Chen CL; Lai ZL; Hsu YL; Lai CH; Hsueh PR; Cho DY
Int J Antimicrob Agents; 2024 Jan; 63(1):107020. PubMed ID: 37898365
[TBL] [Abstract][Full Text] [Related]
58. Real-World Effectiveness of Nirmatrelvir/Ritonavir on Coronavirus Disease 2019-Associated Hospitalization Prevention: A Population-based Cohort Study in the Province of Quebec, Canada.
Kaboré JL; Laffont B; Diop M; Tardif MR; Turgeon AF; Dumaresq J; Luong ML; Cauchon M; Chapdelaine H; Claveau D; Brosseau M; Haddad E; Benigeri M
Clin Infect Dis; 2023 Sep; 77(6):805-815. PubMed ID: 37149726
[TBL] [Abstract][Full Text] [Related]
59. Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in CKD Patients With COVID-19.
Cheng FWT; Yan VKC; Wan EYF; Chui CSL; Lai FTT; Wong CKH; Li X; Zhang IR; Tang SCW; Wong ICK; Chan EWY
Kidney Int Rep; 2024 May; 9(5):1244-1253. PubMed ID: 38707795
[TBL] [Abstract][Full Text] [Related]
60. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.
Hammond J; Leister-Tebbe H; Gardner A; Abreu P; Bao W; Wisemandle W; Baniecki M; Hendrick VM; Damle B; Simón-Campos A; Pypstra R; Rusnak JM;
N Engl J Med; 2022 Apr; 386(15):1397-1408. PubMed ID: 35172054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]